Критерии направления на консультацию к врачу психиатру или на

38
Библиография.
1.
Статистика депрессии
:
http://lossofsoul.com/DEPRESSION/statistic.htm
(2005)
2.
Арана Д., Розенбаум Д. Фармакотерапия психических расстройств /пер. англ./. –
М.: Бином, 2006. – 416 с.
3.
Галако Т. и др. Психиатрия в практике семейного врача /учебно-метод. пособие для врачей/. – Бишкек: ST-Art, 2008ю – 120 с.
4.
Главные вмещательства в ведении депрессии в первичной и специализированной помощи (перев.) - Национальный центр сотрудничества в области психического здоровья (NCCMH, Engl.). – London, 2009. – 102 p.
5.
Глушков В. Депрессии в общемедицинской практике. //РМЖ.- 2005.- т.13.- 12.
6.
Депрессия: Главные вмешательства в ведении депрессии в первичной и специализированной помощи /пер./ – Национальный центр сотрудничества в области психического здоровья (NCCMH, Engl.). – London, 2009. – 102 p
7.
Зурдинова А. и др. Методология разработки и адаптации клинических руководств, основанных на доказательной медицине. – Бишкек, 2008. – 58 с.
8.
Краснов
В.Н.
Закономерности динамики депрессий: клинические, патогенетические и терапевтические аспекты. /В сб. Депрессии и коморбидные расстройства.- М., 1997.- С. 80-98.
9.
Лапин И.П., Оксенбукрг Г.Ф. Intensification of the serotoninergic processes as a possible determination of the thymoleptic effect // Lancet. – 1969. – 1. – P. 132-136.
10.
Марута Н., Мороз В. Невротические депрессии (клиники, патогенез, диагностика и лечение). – Харьков: Арис, 2002. – 144 с.
11.
Михайлов Б.В. Проблема депрессий в общесоматической практике // Межд.
Мед. ж. -2003. – 3. – С. 22-27.
12.
Михайлов Б., Сердюк А., Федосеев В. Психотерапия в общесоматической медицине /Клинич. руководство/. – Харьков, 2002. – 128с.
13.
Мосолов С.Н. Клиническое применение антидепрессантов. – СПб, 1995. – 856 с.
14.
Подкорытов В.С. Проблемы депрессии с общесоматической практике // Архив психиатрии. – 2003. – 1. – С. 69-71.
15.
Смулевич А. Депрессия в общемедицинской практике.- М., 2000. - С.65-72 16.
Флетчер Ф., Флетчер С., Вагнер Э. Клиническая эпидемиология. Основы доказательной медицины. – М., 1998. – 352 с.
17.
Хелл Д. Ландшафт депрессии. – М.: Алетейа, 1999. – 280 с.

39 18.
Abrams R. Electroconvulsive therapy. Oxford Un. press, NY., 2003.
19.
Adli M. et al. Is dose escalation of antidepressants a rational strategy after medium- dose treatment has failed? A systematic review //Eur. Arch. Psychiatry Clin. Neurosci. – 2005. –
255. – 387-400.
20.
American Psychiatric Association. Practice guideline for treatment of patients with major depressive disorder // Am. J. Psychiatry. -2000. – 157. – P.1-45.
21.
Anderson I. SSRIs versus TCA in depressed inpatients^ a meta-analysis of efficacy and tolerability //Depress. Anxiety. – 1998. – 7. – 11-17.
22.
Anderson I. SSRI v.TCA: a meta-analysis //J. Affect. Dis. – 2000. – 58. – 540-542.
23.
Andlin-Sobocki P., Jonsson B., Wittchen H. et al. Cost of brain disorders in Europe //
Europ. J. of neurology. – 2005. – 12. – 1-27.
24.
Baghai T., Moller H-J., Rupprecht R. Recent progress in Pharmacological and non- pharmacological treatment options of major depression // Current pharmaceutical design. – 2006.
– 12. – 503-515.
25.
Baldwin D., Anderson D., Black S. Et al. Guideline for the management of late-life depression in primary care // Int. J. Geriatr. Psychiatry. – 2003. – 18. – P. 829-838.
26.
Barbey J., Roose S. SSRI safety in overdose //J. Clin. Psychiatry. – 1999. – 59. – 42-
48.
27.
Bromet E., Andrade L., Hwang I., et all. Cross-National Epidemiology of DSM-IV
Major Depressive Episode. BMC Medicine, July 2011.
28.
Cheeta S. et al. Antidepressant related death and antidepressant prescriptions in
England and Wales //Br. J. Psychiatry. – 2004. – 184. – 41-47.
29.
CINP (Международное общество нейропсихофармакологии). Технический обзор рабочей группы «Обоснованное применение антидепрессантов». – 2006. –СПб. –
174 с.
30.
Cipriani A., et al. Fluoxetine versus other types of pharmacotherapy for depression//Cochrane. Database. Sist. Rev. 4, CD004185 31.
Colombo C., et al. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression //Psychiatry Res. – 2000. – 95. – 43-53.
32.
Defrance R., et al. Antidepressant and anxiolytic activities of Tianeptine^ an overview of clinic trial..//Clin. Neuropharmacol. 1988. – 11. – 74-82.
33.
Depression. The treatment and management of depression in adults. – NICE clinical guideline. – 2010. – 64 p.
34.
Edwards J., Anderson I. Systematic review and guide to selection of SSRI // Drugs. –
1999. – 57. – 507-533.

40 35.
EST review group. Efficacy and safety of electroconvulsive therapy in depressive disorders.// Lancet. – 2003. – 367. – 153-167.
36.
Feighner J. et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients //J. Clin. Psychiatry. – 1991. – 52. – 329-335.
37.
Ferguson J. SSRI antidepressant medication: adverse effects and tolerability // J. Clin.
Psychiatry. – 2001. – 3. – 22-27.
38.
Frank e. Et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar disorder //Arch. Gen. Psychiatry. – 2005. – 62. – 996-1004.
39.
Hansen R. Et al., Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder //Ann. Intern. Med. – 2005. – 143. – 415-426.
40.
George M.S. et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression //Biol. Psychiatry. – 2005. – 58. – 364-373.
41.
Goldstain B., Goodink P. SSRI in the treatment of affective disorders.//J.
Psychopharmacol. – 1998. – 12. – 55-87.
42.
Hu T.W. The economic burden of depression and reimbursement policy in the Asia
Pacific region //Australas. Psychiatry. – 2004. – 12. – P. 1-15.
43.
Kennedy S.H., et al. Efficacy of escitalopram in the treatment of major depression compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta- analysis //J. Psychiatry Neurosci. – 2005. – 31. – 122-131.
44.
Kielholz P. Multifactorielle depressionsbehandlung. //Arch. Neurol. Psychiatr. -
1983.- 2.- P.215-224.
45.
Kuhs H. et al. Repeated sleep deprivation once versus twice a week in combination with amitriptyline //J. Affect. Disorders. – 1998. – 47. – 97-103.
46.
Lader M. Tolerability and safety: essential in antidepressant pharmacotherapy //J.
Clin. Psychiatry/ - 1996. – 57. – 39-44.
47.
Mace S., Taylor D. SSRI: a review of efficacy and tolerability in depression //
Expert. Opin. Pharmacol. – 2000. – 1. – 917-933.
48.
Markowitz J., et al. A comparative trial of psychotherapy and pharmacotherapy for
“pure” dysthymic patients // J. Affect. Disorders. – 2005. – 89. – 167-175.
49.
Mattia C. Et al. New antidepressants in the treatment of naturopathic pain. A review.//Minevra Anestesiol. 2002. – 68. – 015-114.
50.
Mason J. Et al. Fatal toxicity associated with antidepressant use in primary care //Br.
J. Gen. Pract. 2000. – 50. – 366-370/

41 51.
Mc Ewen B., Olie J. Neurobiology of mood , anxiety and emotion as revealed by studies of a unique antidepressants: Tianeptine // Mol. Psychiatry. – 2005. – 10. – 525-537.
52.
Moller H. Are all antidepressants the same?//J. Clin. Psychiatry. – 2000. – 61. – 24-
28.
53.
Moller H. Suicide, suicidality and suicide prevention in affective disorders //Acta
Med. Scand. – 2003. – Suppl. 2. – 73-80.
54.
Moller H. et al. Double-blind multicenter comparative study of sertraline and amitriphyline in hospitalized patients with major depression //Pharmacopsychiatry. -1998. – 31.
– 179-177.
55.
Montgomery S. Et al. Absence of discontinuation symptoms with paroxetine: a randomized double-blind, placebo-controlled discontinuation study //Int. Clin. Psychopharmacol.
– 2004. – 19. – 271-280.
56.
Montgomery S et al. A randomized study comparing escitalopram with venlafaxine
XR in primary care patients with major depression //Neuropsychobiology. – 2004. – 50. – 57-64.
57.
Moore N. et al. Prospective, multicenter, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorders//Int. Clin. Psychopharmacol. – 2005. – 20. – 131-137.
58.
Mottram P. Et al. Antidepressants for depressed elderly //Cochrane Database Syst.
Rev. - 2006., CD003491 59.
Mulsant B. et al. A twelve-week, double-blind, randomized comparison of nortripthyline and paroxetine in older inpatients and outpatients //Am. J. Geriatr. Psychiatry. –
2—1. – 9. – 239-244.
60.
Normann C. et al., Lamotrigine adjunct paroxetine in acute depression. A placebo, double-blind controlled study //J. Clin. Psychiatry. – 2002. – 63. – 337-344.
61.
Peretti S. et al. Safety and tolerability considerations: TCA/SSRI.//Acta Psychiatr.
Scand. – 2000. – 403. – 17-25.
62.
Pharmacological treatment of mental disorders in primary health care. – WHO guideline, 2009. – 82 p.
63.
Post R., et al., Antidepressant effects of carbamazepin // Am. J. Psychiatry. – 1986. –
143. – 29-34.
64.
Sartorius N. Description and classification of depressive disorders. Contribution for the definition of the therapy resistant and of therapy resistant depression //Pharmacopsychiatry
Neuropharmacol. – 1974. – 7. – 76-79.
65.
Saxena S., Paraje G., Sharan P. Et al. The 10/90 divide in mental health research.
Trends over a 10-year period //Br. J. Psychiatry. – 2006. – 188. – P. 81-82.

42 66.
Sir A. Et al. Randomized trial of sertraline versus venlafaxine XR in major depression. //J. Clin. Psychiatry. – 2005. – 66. – 1312-1320.
67.
Smith D., et al. Efficacy and tolerability of venlafaxine compared with SSRI and other antidepressants: a meta-analysis //Brit. J. Psychiatry. – 2002. – 180. – 396-404.
68.
Stahl S. et al. SNRIs: their pharmacology, clinical efficacy and tolerability in comparison with other classes of antidepressants //CNS Spectr. - 2005. – 10. – 732-747.
69.
Szanto K. et al. Occurrence and course of suicidality during short-term treatment of late-life depression //Arch. Gen. Psychiatry. – 2003. – 60. – 610-617.
70.
Thomas C., Morris S. Cost of depression among adults in England //Br. J. Psychiatry.
– 2003. – 183. – P. 514-519.
71.
Tollefson G. et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression //Int. Psychogeriatr. – 1995. – 7. – 89-104.
72.
van Amerongen A. et al. A randomized, double-blind comparison of milnacipran and imipramine in the treatment of depression //J. Affect. Disord. - 2002. – 72. – 21-31.
73.
Vis P., et al. Duloxetine and venlafaxine –XR in the treatment of major depression: a meta-analysis of randomized trials // Ann. Pharmacother. – 2005. – 39. – 1798-1807.
74.
Volz H., Laux P. Potential treatment for sub threshold and mild depression: a comparison of St.John’s wort extracts and fluoxetine //Compr. Psychiatry. – 2000. – 41. – 133-
137.
75.
Waldinger M. Et al. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study.//J. Clin. Psychiatry. – 1998. – 18. – 274-281.
76.
Weissman M. et al. Comprehensive Guide to interpersonal psychotherapy. – NY,
2000. – 456 p.
77.
Wilde M., Benfield P. Tianeptine. A review of its pharmacodinamic and pharmacokinetic properties and therapeutic efficacy in depression and coexisting anxiety and depression //Drugs. – 1995. – 49. – 411-439.
78.
Wu J. et al. The biological basis of an antidepressant response to sleep deprivation and relapse //Am. J. Psychiatry. – 1990. – 147. – 14-21.

43

Скачать 0,49 Mb.

Поделитесь с Вашими друзьями: